ParaPRO

Executive Summary

ParaPRO is a privately held specialty pharmaceutical company dedicated to addressing the growing challenge of parasitic infestations, particularly head lice and scabies. Founded in 1999 and headquartered in Carmel, Indiana, the company leverages its proprietary spinosad-based formulation to overcome widespread resistance to conventional treatments. Its lead product, Natroba (spinosad topical suspension), is FDA-approved for head lice and has demonstrated high efficacy and safety. ParaPRO's mission is to reduce the personal, public health, and economic burdens of these infestations, which affect millions globally. The company's focus on a naturally derived compound positions it uniquely in a market where treatment failures are common due to resistance. Looking ahead, ParaPRO aims to expand its pipeline into scabies, a neglected tropical disease with significant unmet need. The company is also exploring pediatric formulations and strategic partnerships to broaden its global reach. Although privately held and with limited public data, ParaPRO's differentiated product and strong market fit suggest potential for growth. Its success hinges on regulatory approvals, clinical trial outcomes, and commercial execution. With a proven track record in head lice and a clear path into scabies, ParaPRO represents a focused player in the parasiticides market.

Upcoming Catalysts (preview)

• Q1 2027FDA Approval for Scabies Indication65% success
• Q3 2026Partnership with Global Pharma for Distribution60% success
• Q4 2026Publication of Phase 3 Pediatric Scabies Trial Results75% success